JP Morgan Private Wealth Advisors’s Quest Diagnostics DGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | $1.89M | Sell |
15,492
-836
| -5% | -$111K | 0.01% | 756 |
|
|
2023
Q2 | $2.3M | Sell |
16,328
-3,223
| -16% | -$444K | 0.01% | 517 |
|
|
2023
Q1 | $2.77M | Sell |
19,551
-2,448
| -11% | -$350K | 0.01% | 762 |
|
|
2022
Q4 | $3.44M | Sell |
21,999
-6,349
| -22% | -$912K | 0.01% | 679 |
|
|
2022
Q3 | $3.48M | Sell |
28,348
-425
| -1% | -$56K | 0.01% | 661 |
|
|
2022
Q2 | $3.83M | Sell |
28,773
-2,855
| -9% | -$389K | 0.01% | 647 |
|
|
2022
Q1 | $4.33M | Buy |
31,628
+9,650
| +44% | +$1.35M | 0.01% | 663 |
|
|
2021
Q4 | $3.8M | Buy |
21,978
+4,574
| +26% | +$696K | 0.01% | 689 |
|
|
2021
Q3 | $2.53M | Sell |
17,404
-6,443
| -27% | -$943K | 0.01% | 806 |
|
|
2021
Q2 | $3.15M | Buy |
23,847
+1,868
| +8% | +$245K | 0.01% | 715 |
|
|
2021
Q1 | $2.82M | Buy |
21,979
+5,274
| +32% | +$650K | 0.01% | 654 |
|
|
2020
Q4 | $1.99M | Sell |
16,705
-3,057
| -15% | -$373K | 0.01% | 726 |
|
|
2020
Q3 | $2.26M | Buy |
19,762
+11,996
| +154% | +$1.42M | 0.01% | 619 |
|
|
2020
Q2 | $885K | Buy |
7,766
+77
| +1% | +$8.17K | ﹤0.01% | 857 |
|
|
2020
Q1 | $617K | Buy |
7,689
+369
| +5% | +$38.2K | ﹤0.01% | 856 |
|
|
2019
Q4 | $782K | Sell |
7,320
-1,507
| -17% | -$157K | ﹤0.01% | 885 |
|
|
2019
Q3 | $945K | Buy |
8,827
+914
| +12% | +$93.8K | ﹤0.01% | 774 |
|
|
2019
Q2 | $806K | Buy |
7,913
+447
| +6% | +$43K | ﹤0.01% | 817 |
|
|
2019
Q1 | $671K | Buy |
7,466
+259
| +4% | +$22.4K | ﹤0.01% | 919 |
|
|
2018
Q4 | $600K | Buy |
7,207
+463
| +7% | +$43.4K | ﹤0.01% | 900 |
|
|
2018
Q3 | $728K | Sell |
6,744
-316
| -4% | -$34.7K | ﹤0.01% | 933 |
|
|
2018
Q2 | $776K | Sell |
7,060
-171
| -2% | -$17.8K | ﹤0.01% | 853 |
|
|
2018
Q1 | $726K | Buy |
7,231
+57
| +0.8% | +$5.84K | ﹤0.01% | 742 |
|
|
2017
Q4 | $706K | Buy |
7,174
+1,997
| +39% | +$189K | ﹤0.01% | 760 |
|
|
2017
Q3 | $485K | Sell |
5,177
-283
| -5% | -$30K | ﹤0.01% | 859 |
|
|
2017
Q2 | $607K | Sell |
5,460
-479
| -8% | -$50.6K | ﹤0.01% | 775 |
|
|
2017
Q1 | $583K | Buy |
5,939
+1,666
| +39% | +$159K | ﹤0.01% | 794 |
|
|
2016
Q4 | $393K | Sell |
4,273
-6,327
| -60% | -$545K | ﹤0.01% | 893 |
|
|
2016
Q3 | $897K | Buy |
10,600
+339
| +3% | +$28.5K | 0.01% | 615 |
|
|
2016
Q2 | $835K | Sell |
10,261
-185
| -2% | -$14.1K | 0.01% | 640 |
|
|
2016
Q1 | $747K | Buy |
10,446
+4,633
| +80% | +$311K | 0.01% | 629 |
|
|
2015
Q4 | $413K | Buy |
5,813
+1,317
| +29% | +$88.5K | ﹤0.01% | 749 |
|
|
2015
Q3 | $276K | Sell |
4,496
-914
| -17% | -$63.9K | ﹤0.01% | 819 |
|
|
2015
Q2 | $392K | Buy |
5,410
+1,336
| +33% | +$98.6K | ﹤0.01% | 759 |
|
|
2015
Q1 | $313K | Sell |
4,074
-921
| -18% | -$66K | ﹤0.01% | 874 |
|
|
2014
Q4 | $335K | Sell |
4,995
-836
| -14% | -$52.8K | ﹤0.01% | 838 |
|
|
2014
Q3 | $354K | Buy |
5,831
+1,805
| +45% | +$111K | ﹤0.01% | 795 |
|
|
2014
Q2 | $236K | Buy |
+4,026
| New | +$236K | ﹤0.01% | 766 |
|
Other funds holding DGX
JP Morgan Private Wealth Advisors's DGX Position: Q3 2023 in Review
JP Morgan Private Wealth Advisors reduced its Quest Diagnostics (DGX) stake by 5.1% in Q3 2023, selling an estimated $111K and leaving 15,492 shares worth $1.89M. The position accounts for 0.01% of the portfolio, ranked #756.
JP Morgan Private Wealth Advisors first reported a position in DGX in Q2 2014 and has held it in 38 quarters since. The position peaked at $4.33M in Q1 2022. 795 funds tracked by Wall St. Rank hold DGX as of Q3 2023.
- JP Morgan Private Wealth Advisors held 15,492 shares of Quest Diagnostics worth $1.89M as of Q3 2023.
- JP Morgan Private Wealth Advisors sold 836 Quest Diagnostics shares in Q3 2023, an estimated $111K.
- Quest Diagnostics made up 0.01% of JP Morgan Private Wealth Advisors's portfolio in Q3 2023, its #756 holding.
- JP Morgan Private Wealth Advisors first reported a position in Quest Diagnostics in Q2 2014 and has held it in 38 quarters since.
- JP Morgan Private Wealth Advisors's Quest Diagnostics position peaked at $4.33M in Q1 2022.
- 795 funds tracked by Wall St. Rank held Quest Diagnostics as of Q3 2023.
Based on JP Morgan Private Wealth Advisors's 13F filing for Q3 2023, filed 8 Nov 2023.